| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | 193.00▲ | 208.00▼ |
| MA10 | N/A | N/A | N/A | 200.50▲ | 218.25▼ |
| MA20 | N/A | N/A | N/A | 212.00▼ | 206.50▼ |
| MA50 | N/A | N/A | N/A | 215.77▼ | 193.20▲ |
| MA100 | N/A | N/A | N/A | 201.14▲ | 210.69▼ |
| MA200 | N/A | N/A | N/A | 194.40▲ | 239.09▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | -2.831▼ | -2.722▼ |
| RSI | N/A | N/A | N/A | 44.495▼ | 49.734▼ |
| STOCH | N/A | N/A | N/A | 17.446▼ | 40.208 |
| WILL %R | N/A | N/A | N/A | -55.085 | -71.809 |
| CCI | N/A | N/A | N/A | -45.052 | -94.016 |
|
Wednesday, June 11, 2025 07:46 PM
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in ...
|
|
Wednesday, May 14, 2025 05:00 PM
TURKU, FI / ACCESS Newswire / May 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Overcoming immune resistance in HR-MDS: Detailed safety and efficacy Phase II data on bexmarilimab to be ...
|
|
Thursday, April 17, 2025 01:45 AM
TURKU, FI / ACCESS Newswire / April 17, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/06/25 | 190.00 | 205.00 | 190.00 | 202.50 | 49,456 |
| 27/06/25 | 186.00 | 195.00 | 186.00 | 190.00 | 10,171 |
| 26/06/25 | 191.10 | 191.10 | 176.00 | 185.00 | 56,634 |
| 25/06/25 | 195.00 | 197.00 | 191.00 | 192.50 | 17,824 |
| 24/06/25 | 197.50 | 199.00 | 193.00 | 195.00 | 6,715 |
| 23/06/25 | 202.50 | 206.10 | 195.00 | 197.50 | 2,940 |
| 20/06/25 | 202.50 | 206.10 | 195.75 | 202.50 | 1,356 |
| 19/06/25 | 212.50 | 220.00 | 198.00 | 202.50 | 36,690 |
| 18/06/25 | 222.50 | 230.00 | 214.60 | 215.00 | 16,327 |
| 17/06/25 | 222.50 | 230.00 | 221.50 | 222.50 | 1,612 |
|
|
||||
|
|
||||
|
|